Observation time on subsequent injections of subcutaneous daratumumab may be safely removed from institutional policies to reduce chair time.
Monica Tadros, PharmD, BCPS, BCOP
Advertisement
Articles by Monica Tadros, PharmD, BCPS, BCOP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Therapeutic Cancer Vaccines: Are We There Yet?
2
Walgreens Strengthens Vaccine Access Through Digital Tools, Pharmacist Education
3
Transforming HER2+ Metastatic Breast Cancer Treatment With Targeted ADC Therapy
4
Subcutaneous Amivantamab Shows Promise in EGFR-Mutated Lung Cancer
5
